The pharmaceutical and healthcare sector is one of the world’s most vital and innovative.
Against a backdrop of technological change and an increasing and aging population, we partner with our clients to help them achieve their goals, capitalise on opportunities and navigate uncertainty.
Combining deep scientific, technical and strategic knowledge we help our clients by providing the commercial nous, experience and range of services that only a large international professional services firm can offer, to anticipate and deliver innovative and value-enhancing solutions.
in connection with the Relationship Agreement and settlement reached with the Company’s largest shareholder, the activist investor Scopia Management
on its acquisition of assets relating to the research, development, manufacture and marketing of glial-cell line-derived neurotrophic factor (GDNF), a potentially disease-modifying treatment for Parkinson's disease
on its acquisition of Yposkesi, a French market leader in gene therapy and viral vector manufacturing
Acacia Research Corporation
on its entry into an agreement with Link Fund Solutions Limited to purchase shares in up to 19 public and private life sciences companies from the LF Equity Income Fund for up to £223.9 million.
a company representing pharmaceutical wholesalers, on regulatory affairs and intellectual property matters
in relation to the launch and correct classification of new products based on a disruptive technology for extracting microRNA from plants, including advising on strategy to mitigate risks related to a misclassification under the contiguous categories of medicinal products, novel food and food supplements
Insights and updates
Natalie is a Corporate and Mergers & Acquisitions partner with particular expertise in healthcare, aged care and advisory and transactional work for government clients. Natalie is Herbert Smith Freehills’ Sector Lead Partner for Healthcare.